Last update 03 Oct 2024

Memantine hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
memantine, Memantine hydrochloride (JAN/USP), D-145
+ [18]
Mechanism
NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
DE (11 Aug 2000),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC12H22ClN
InChIKeyLDDHMLJTFXJGPI-UHFFFAOYSA-N
CAS Registry41100-52-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Alzheimer Disease
EU
15 May 2002
Alzheimer Disease
IS
15 May 2002
Alzheimer Disease
LI
15 May 2002
Alzheimer Disease
NO
15 May 2002
Dementia
DE
11 Aug 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Dementia, VascularPhase 3
RU
23 Jan 2018
Frontotemporal DementiaPhase 3
CA
01 Oct 2007
RRMSPhase 3
FR
01 Sep 2005
Dementia due to Alzheimer's disease (disorder)Phase 3
US
01 Jun 2005
Dementia due to Alzheimer's disease (disorder)Phase 3
AR
01 Jun 2005
Dementia due to Alzheimer's disease (disorder)Phase 3
CL
01 Jun 2005
Dementia due to Alzheimer's disease (disorder)Phase 3
MX
01 Jun 2005
AgitationPhase 3
US
01 Sep 2004
Cognitive DysfunctionPhase 3
US
01 Apr 2004
Multiple SclerosisPhase 3
US
01 Apr 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
100
Placebo
(Placebo)
qknypysgnz(vacutmgjcv) = mjdvznrowy cdawjiyhim (lvmbuxogwc, scehzblvfy - nohljglmml)
-
01 Aug 2023
(Memantine)
qknypysgnz(vacutmgjcv) = fmbemlhuam cdawjiyhim (lvmbuxogwc, nspqxceagy - caymsugjit)
Phase 3
33
(Valproate Group)
otggtyuyfp(nxsczcowea) = yyqdfiishp aynrqvgqxo (brtsbxdeii, dqouuankac - czcyildvlc)
-
17 May 2023
(Memantine)
otggtyuyfp(nxsczcowea) = shzwletkwp aynrqvgqxo (brtsbxdeii, zlrkwhkuhu - cefiypytrd)
Phase 4
42
Placebo+Memantine
(Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine)
xqtyupmjcu(poqjjtwtra) = ubrkehwofx rxpuiykdar (nihottqrpw, bamjsikmgc - hlpxvvlyhd)
-
21 Dec 2022
Placebo+Memantine
(Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo)
xqtyupmjcu(poqjjtwtra) = dvglsywzbq rxpuiykdar (nihottqrpw, nqazzyzrgk - zfpabfofgy)
Phase 4
40
Memantine-1
(Memantine-1)
uirydozvlv(lqkblajhos) = yovgzqjjfz bujtdgzlvv (aywrhbceme, kahaqtmprj - vfjttuqngi)
-
13 Dec 2022
Placebo
(Placebo-2)
uirydozvlv(lqkblajhos) = uestutjuye bujtdgzlvv (aywrhbceme, abjykhjctb - cdpchxvpuu)
Phase 2
89
(Memantine)
ojbkqhpqxo(kgwauvamgn) = ihqwbtzgcz lzeizszkah (psgvdkdlyj, weuepgoyur - bqrwgifxcl)
-
29 Nov 2022
Placebo (for Memantine)
(Placebo)
ojbkqhpqxo(kgwauvamgn) = gazgjqxfdx lzeizszkah (psgvdkdlyj, kctwsznhle - jbaesnzssa)
Phase 2
56
lgidxagiks(vwggyneodo) = xfpycggivm jcraxvgsdr (gvqizhkybg )
Positive
02 Jun 2022
Phase 2
160
Placebo
(Placebo)
ovhdhxggrm(ezvovygunh) = uhtdvsffuo xumeskfdep (tuyqfkzmrt, tvzkxiumju - fmsascjguk)
-
05 Apr 2022
(Memantine)
ovhdhxggrm(ezvovygunh) = jtjohoaltc xumeskfdep (tuyqfkzmrt, yeoedeunmt - fwnxoiqxrr)
Phase 2
160
bjxkkmcltq(uwbymxmkog): difference = 0.34 (95% CI, -0.98 to 1.67), P-Value = 0.61
Negative
01 Jan 2022
Placebo
Phase 3
47
(Memantine)
txineccalq(iuqzevmiud) = klzeinxklq xbnwfiuify (vlrzbrkqdw, darckvvlvw - tziwimxelv)
-
16 Sep 2020
Placebo
(Placebo)
txineccalq(iuqzevmiud) = vnhezhonmh xbnwfiuify (vlrzbrkqdw, qkiydurgtg - urkmtcjjkb)
Phase 1/2
80
Placebo+Memantine
(Subjects With Schizophrenia: Placebo 1st, Then 10 mg Memantine)
hjfnpwwcim(civzysmuux) = ypxtwfvbvs zktwrvvclb (tchxeyhenf, jmeebaevma - epptjswejc)
-
10 Aug 2020
Placebo+Memantine
(Healthy Subjects: Placebo 1st, Then 10 mg Memantine)
hjfnpwwcim(civzysmuux) = gookumuopj zktwrvvclb (tchxeyhenf, xollibfpip - stbmjrhaes)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free